Trovagene Inc. (NASDAQ:TROV) traded down 4.5% during mid-day trading on Monday . The company traded as low as $4.75 and last traded at $4.88, with a volume of 273,013 shares traded. The stock had previously closed at $5.11.

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald lowered shares of Trovagene from a “buy” rating to a “hold” rating and cut their price target for the stock from $9.00 to $5.00 in a report on Monday, April 25th. Piper Jaffray Cos. lowered shares of Trovagene from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $5.26 to $8.00 in a report on Monday, April 25th. Maxim Group reissued a “buy” rating on shares of Trovagene in a report on Monday, June 6th. Avondale Partners reissued a “market perform” rating and issued a $6.00 price target on shares of Trovagene in a report on Tuesday, March 29th. Finally, Zacks Investment Research raised shares of Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $6.96.

The firm’s market capitalization is $146.32 million. The stock’s 50-day moving average price is $4.81 and its 200 day moving average price is $4.78.

Trovagene (NASDAQ:TROV) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.07. Equities analysts anticipate that Trovagene Inc. will post ($1.30) earnings per share for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.